gene mutations/polymorphisms might have on glucocorticoid signal transduction indicates that alterations in hGR action may have important implications for many critical biological processes, such as the behavioral and physiological responses to stress, the immune and inflammatory reaction, as well as growth and reproduction.
Introduction
In humans, glucocorticoids regulate a broad spectrum of physiological functions essential for life and play an important role in the maintenance of basal and stressrelated homeostasis [1] [2] [3] . Approximately 20% of the genes expressed in human leukocytes are regulated positively or negatively by glucocorticoids [4] . Glucocorticoids are involved in almost every cellular, molecular and physiological network of the organism and play a pivotal role in critical biological processes, such as growth, reproduction, intermediary metabolism, immune and inflammatory reactions, as well as central nervous system and cardiovascular functions [1, 4] . Furthermore, glucocorticoids represent one of the most widely used therapeutic compounds often employed in the treatment of inflammatory, autoimmune and lymphoproliferative disorders [1] .
The Human Glucocorticoid Receptor
At the cellular level, the actions of glucocorticoids are mediated by a 94-kDa protein, the glucocorticoid receptor (GR). The human (h) GR belongs to the steroid/thyroid/retinoic acid superfamily of nuclear receptors and functions as a ligand-dependent transcription factor that regulates the expression of glucocorticoid-responsive genes positively or negatively [5] [6] [7] ( fig. 1 ). The hGR cDNA was isolated by expression cloning in 1985 [8] . The hGR gene is one locus on the long arm of chromosome 5 (q31.3) and consists of 9 exons. Alternative splicing of the hGR gene in exon 9 generates two highly homologous receptor isoforms, termed ␣ and ␤ . These are identical through amino acid 727, but then diverge, with hGR ␣ having an additional 50 amino acids and hGR ␤ having an additional, nonhomologous 15 amino acids [3, [5] [6] [7] ( fig. 1 ). The hGR ␣ represents the classic glucocorticoid receptor that functions as a ligand-dependent transcription factor, while the hGR ␤ does not bind glucocorticoid agonists, has intrinsic, hGR ␣ -independent, gene-specific transcriptional activity, and exerts a dominant negative effect upon the transcriptional activity of hGR ␣ [9, 10] . Expressed hGR ␣ is a panel of 8 amino terminal translational isoforms of varying lengths, each of which consists of three subdomains, the N-terminal (NTD), the DNAbinding (DBD) and the ligand-binding (LBD) domain. These hGR ␣ isoforms differ at their amino-termini and may differentially transduce the glucocorticoid signal to target tissues depending on their selective relative expression and inherent activities. It is likely that similar differential cell-specific production and functional differences might also be present between the putative hGR ␤ translational isoforms [5, 6] . This marked complexity in the transcription/translation of the hGR gene enables target tissues to differentially respond to circulating glucocorticoid concentrations and accounts for the highly stochastic nature of the glucocorticoid signaling pathway [11] .
In the absence of ligand, hGR ␣ resides mostly in the cytoplasm of cells as part of a hetero-oligomeric complex, which contains chaperon heat shock proteins (HSPs) 90, 70 and FKBP51, as well as other proteins [7, 11] . Upon ligand-induced activation, the hGR ␣ dissociates from this multiprotein complex and translocates into the nucleus, where it binds as a homodimer to glucocorticoid response elements (GREs) in the promoter regions of target genes and regulates their expression positively or negatively, depending on GRE sequence and promoter context [7, 11] ( fig. 2 ) . To initiate transcription, the hGR ␣ uses its transcriptional activation domains, activation function (AF)-1 and AF-2, located in the NTD and LBD, respectively, as surfaces to interact with nuclear receptor coactivators and chromatin-remodeling complexes [12] [13] [14] [15] . The ligand-activated hGR ␣ can also modulate gene expression independently of DNA-binding, by interacting, possibly as a monomer, with other transcription factors, such as nuclear factor-B, activator protein-1, p53 and signal transducers and activators of transcription [7] . Following transcriptional activation or inhibition of glucocorticoidresponsive genes, the hGR ␣ dissociates from the ligand and has a lower affinity for binding to GREs. The unliganded hGR ␣ remains within the nucleus for a considerable length of time and is then exported to the cytoplasm; both within the nucleus and within the cytoplasm the hGR ␣ may be recycled and/or degraded in the proteasome [16] ( fig. 2 ) .
Alterations in the molecular mechanisms of hGR ␣ action may lead to alterations in tissue sensitivity to glucocorticoids, which may take the form of glucocorticoid resistance or glucocorticoid hypersensitivity and may be associated with significant morbidity [17] [18] [19] ( table 1 ). In the present review, we summarize the pathophysiology and molecular mechanisms underlying primary generalized glucocorticoid resistance and hypersensitivity. Nucleocytoplasmic shuttling of the glucocorticoid receptor. Upon binding to the ligand, the activated hGR ␣ dissociates from heat shock proteins (HSPs) and translocates into the nucleus, where it homodimerizes and binds to glucocorticoid response elements (GREs) in the promoter region of target genes or interacts with other transcription factors (TFs), such as activator protein-1 (AP-1), nuclear factor-B (NF-B) and signal transducer and activator of transcription-5 (STAT5), ultimately modulating the transcriptional activity of respectively GRE-or TFREcontaining genes. 
Primary Generalized Glucocorticoid Resistance and Hypersensitivity

Clinical Manifestations
Primary generalized glucocorticoid resistance (PGGR) is a rare, familial or sporadic condition, initially described and elucidated by Chrousos and coworkers [20] [21] [22] . PGGR is characterized by generalized, partial, target-tissue insensitivity to glucocorticoids, which leads to compensatory activation of the hypothalamic-pituitary-adrenal (HPA) axis and hypersecretion of adrenocorticotropic hormone (ACTH) in the systemic circulation. The latter results in adrenocortical hyperplasia, increased cortisol secretion as a compensation for the reduced action of glucocorticoids at target tissues, and increased production of adrenal steroids with mineralocorticoid (cortisol, deoxycorticosterone (DOC) and corticosterone) and/or androgenic activity (androstenedione, dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS)) [20] [21] [22] .
The clinical manifestations of PGGR reflect the pathophysiological alterations described above and primarily include manifestations of mineralocorticoid and/or androgen excess [20] [21] [22] . Clinical manifestations of glucocorticoid deficiency might occur, but are rare and were only reported in a young child with hypoglycemic generalized tonic-clonic seizures during the course of a febrile illness [23] , in a newborn baby with severe hypoglycemia, excessive fatigability with feeding, increased susceptibility to infections and concurrent growth hormone deficiency [24] , and in several adult patients with chronic fatigue [20] [21] [22] . Clinical manifestations of mineralocorticoid excess include hypertension and hypokalemic alkalosis. Clinical manifestations of androgen excess include ambiguous genitalia in a karyotypic female at birth and gonadotropin-independent precocious puberty in children of either gender; acne, hirsutism and hypofertility in both sexes; male-pattern hair loss, menstrual irregularities and oligo-anovulation in females, and oligospermia in males [20] [21] [22] . The clinical spectrum of the condition is broad, ranging from most severe to mild forms, while a number of patients may be asymptomatic, displaying biochemical alterations only [20] [21] [22] . This variable clinical phenotype is due to variations in the tissue sensitivity of the glucocorticoid, mineralocorticoid and/or androgen receptor signaling pathways; variations in the activity of key hormone-inactivating or hormoneactivating enzymes, such as 11 ␤ -hydroxysteroid dehydrogenase [25] and 5 ␣ -reductase [26] , and other genetic or epigenetic factors, such as the presence of insulin resistance and visceral obesity [21] . In recognition of Professor George P. Chrousos' extensive and ground-breaking research work in this field, it has been proposed that the term 'Chrousos syndrome' is used in place of 'primary generalized glucocorticoid resistance' [27] .
Primary generalized glucocorticoid hypersensitivity (PGGH) represents the mirror image of PGGR, and is characterized by generalized, partial, target-tissue hypersensitivity to glucocorticoids, and compensatory hypoactivation of the HPA axis. To date there has been only one patient reported with manifestations of tissue-specific 
Molecular Mechanisms hGR Mutations
The molecular basis of PGGR has been ascribed primarily to mutations in the hGR gene, which impair the molecular mechanisms of hGR action and decrease tissue sensitivity to glucocorticoids ( table 2 ; fig. 3 ) [23, 24, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . The molecular defects that have been elucidated in cases with PGGR and have been reported to date are summarized in table 2 . Compared with the wild-type receptor, all mutant receptors demonstrated variable reduction in their ability to transactivate glucocorticoid-responsive genes in response to dexamethasone [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . The mutant receptors hGR ␣ I559N, hGR ␣ F737L, hGR ␣ I747M and hGR ␣ L773P exerted a dominant negative effect upon the wild-type receptor, which might have contributed to manifestation of the disease at the heterozygote state [29, 33, 35, 37, 40] . All mutant receptors in which the mutations were located in the LBD of the receptor showed a variable reduction in their affinity for the ligand [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . The only mutant receptor that demonstrated normal affinity for the ligand was the hGR ␣ R477H, in which the mutation was located in the DBD [39] . Most pathologic mutant receptors were observed primarily in the cytoplasm of cells in the absence of ligand, except for the hGR ␣ V729I and hGR ␣ F737L receptors, which were localized both in the cytoplasm and the nucleus of cells. Exposure to dexamethasone induced a slow translocation of the mutant receptors into the nucleus, which ranged from 20 to 180 min compared with the wild-type hGR ␣ , which required only 12 min for complete translocation [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . All mutant receptors in which the mutations were located in the LBD preserved their ability to bind to DNA and displayed an abnormal interaction with the glucocorticoid receptor-interacting protein-1 (GRIP1) coactivator in vitro [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . The only mutant receptor that failed to bind to DNA but displayed a normal interaction with the GRIP1 coactivator was the hGR ␣ R477H, in which the mutation was located at the C-terminal zinc finger of the DBD [39] .
In the patient with the symptomatology suggestive of PGGH, we identified a novel, heterozygous guanine to cytosine (G ] C) substitution at nucleotide position 1201 in exon 2 of the hGR gene, resulting in aspartic acid (D) to histidine (H) substitution at amino acid position 401 in the NTD of the receptor. Functional studies showed that compared with the wild-type hGR ␣ , the hGR ␣ D401H demonstrated a 2.4-fold increase in its ability to transactivate the glucocorticoid-responsive genes and exerted a dominant positive effect upon the wildtype receptor at low concentrations. The mutant receptor hGR ␣ D401H had similar affinity for the ligand and time to nuclear translocation, it preserved its ability to bind to GREs, and displayed a normal interaction with the GRIP1 coactivator [28] ( table 2 ) .
hGR Polymorphisms
Further to the hGR gene mutations, interindividual variations in tissue sensitivity to glucocorticoids have been described within the normal population and have been partly attributed to polymorphisms in the hGR gene. Several polymorphisms of the hGR gene have been reported to date [42] [43] [44] . The first polymorphism, ER22/23EK, consists of two linked, single-nucleotide mutations in codons 22 and 23 in exon 2 of the hGR gene (rs 6189 and rs 6190). The first mutation in codon 22 is silent, not resulting in an amino acid change (GAG to GAA, both coding for glutamic acid (E)), but the second mutation in codon 23 (AGG to AAG) results in arginine (R) to lysine (K) substitution [44, 45] . The ER22/23EK polymorphism results in a significant reduction of the transcriptional activation of glucocorticoid-responsive genes compared with the wild-type receptor, but it does not influence transcriptional repression [45] . This polymorphism reduces sensitivity to glucocorticoids, as evidenced by the higher serum cortisol concentrations and the smaller decrease in cortisol concentrations following dexamethasone suppression testing in carriers compared with noncarriers [46] , and results in a phenotype that is characterized by a more favorable metabolic profile, leading to longevity. Carriers of the ER22/23EK polymorphism display relative glucocorticoid resistance, lower fasting insulin concentrations and improved insulin sensitivity, lower total and LDL cholesterol concentrations and lower CRP concentrations [44, 47] . These effects of the ER22/23EK polymorphism suggest a healthier cardiovascular and metabolic profile, which was confirmed in a follow-up study demonstrating an increased survival rate for carriers of this polymorphism over a 4-year period compared with noncarriers [47] . In line with this favorable metabolic profile, the ER22/23EK polymorphism is significantly higher in the oldest half of the population and is associated with increased survival. At young age, a sexually dimorphic pattern in body composition has been documented. Male ER22/23EK carriers are taller, have more muscle mass, and are stronger than noncarriers. Female ER22/23EK carriers have smaller waist and hip circumferences and lower body weight [48] . Finally, at older age, carriers of the ER22/23EK polymorphism have lower risk of dementia and fewer white matter lesions in the brain compared to noncarriers [44] . The molecular mechanisms through which the ER22/23EK polymorphism produces the above effects are likely to involve a higher expression of the hGR ␣ -A (94 kDa) isoform at the expense of the hGR ␣ -B (91 kDa) isoform. Given that the latter isoform has greater transactivational activity, the shift in hGR ␣ -A to hGR ␣ -B expression ratio leads to an overall decrease in transcriptional activity [49] ( fig. 4 ) .
Further downstream in exon 2, a polymorphism was identified that changes codon 363 from AAT to AGT (rs 6195), resulting in a serine (N) for asparagine (S) substitution. The N363S polymorphism is associated with higher sensitivity to glucocorticoids in vivo, resulting in a significant increase in the transcriptional activation of glucocorticoid-responsive genes compared with the wildtype receptor, although it does not influence transcriptional repression [45] . The N363S polymorphism is associated with higher sensitivity to glucocorticoids in vivo, increased insulin response to exogenous dexamethasone administration [44, 50] , higher BMI [44, [50] [51] [52] [53] , higher waist-to-hip ratio [54] , and a tendency toward lower bone mineral density in trabecular bone [50, 51] . The N363S variant is also associated with elevated cholesterol and triglyceride concentrations and higher incidence of coronary artery disease independent of weight [51, 55] ( fig. 4 ) . The molecular mechanism through which the N363S polymorphism exerts its effects is unknown. It has been postulated that this polymorphism contributes a new serine residue for phosphorylation, whereby protein interactions with transcription cofactors might be altered.
A frequent Bcl I restriction fragment length polymorphism (rs 41423247) is also associated with increased sensitivity to glucocorticoids, hypertension, visceral adipocity [44, 56, 57] and increased insulin concentrations in obese women [58] . The exact mutation of this polymorphic site was identified as a C ] G substitution in intron 2. In the elderly, the G allele of the Bcl I polymorphism is associated with a lower BMI and a tendency towards lower lean body mass, which is likely to arise as a result of the increased sensitivity to glucocorticoids [59] ( fig. 4 ) .
The TthIII I variant (rs10052957) is a restriction site length polymorphism in the promoter region of the hGR gene, which is not functional by itself [44] . However, the ER22/23EK variant was found to be invariably linked to the TthIII I polymorphism. Therefore, associations with glucocorticoid resistance and healthier metabolic profile observed in the TthIII I carriers are likely to arise as a result of the ER22/23EK polymorphism.
Finally, a single nucleotide polymorphism that replaces A with G at the nucleoside 3669 (A3669G) (rs 6198) located in the 3 end of exon 9 ␤ has also been described [60] . This polymorphism does not change the amino acid sequence but increases the stability of hGR ␤ mRNA and hGR ␤ protein expression, leading to greater inhibition of hGR ␣ -induced transcriptional activity and glucocorticoid resistance. The presence of the A3669G allele is associated with reduced central obesity and a more favorable lipid profile in affected subjects [60] . Furthermore, this polymorphism selectively affects the transrepressive activity of the glucocorticoid receptor and is associated with an increased inflammatory state, rheumatoid arthritis and cardiovascular disease [61] [62] [63] [64] [65] [66] .
Clinical Evaluation
The first step in evaluating a patient with suspected alterations in tissue sensitivity to glucocorticoids is to obtain a complete personal and family history, with particular attention to evidence suggesting alterations in the activity of the HPA axis. In addition, any evidence suggesting possible CNS dysfunction, such as headaches, visual impairment or seizures, should be noted. In female subjects, the regularity of menstrual cycles should be documented. In children and adolescents, growth and sexual maturation should be evaluated carefully. The physical examination should include an assessment for signs of hyperandrogenism, virilization and glucocorticoid excess, as well as a complete neurologic examination. Arterial blood pressure should be recorded and preferably monitored over a 24-hour period.
Endocrinologic Evaluation
The concentrations of plasma ACTH, plasma renin activity (recumbent and upright) and aldosterone, as well as those of serum cortisol, testosterone, androstenedione, DHEA, DHEAS, total cholesterol, HDL, LDL, triglycerides, and fasting glucose and insulin should be recorded in the morning. Determination of the 24-hour urinary free cortisol (UFC) excretion on 2 or 3 consecutive days is central to the diagnosis, given that patients with PGGR demonstrate increased 24 h UFC excretion in the absence of clinical manifestations suggestive of hypercortisolism. In patients with PGGR, the rise in serum cortisol and androgen concentrations, as well as in the 24 h UFC exretion varies considerably depending on the severity of impairment of glucocorticoid signal transduction. In most severe cases, serum cortisol and 24 h UFC concentrations may be, respectively, up to 7-and 50-fold higher than the upper limit of normal range. Plasma ACTH concentrations may be normal or high in PGGR and normal or low in PGGH.
The responsiveness of the HPA axis to exogenous glucocorticoids should also be tested with dexamethasone in patients suspected to have PGGR. Increasing doses of dexamethasone (0.3, 0.6, 1.0, 1.5, 2.0, 2.5 and 3.0 mg) should be given orally at midnight every other day, and a serum sample should be drawn at 08.00 h the following morning for determination of serum cortisol and dexamethasone concentrations. The concurrent measurement of serum dexamethasone concentrations is suggested in order to exclude the possibility of nonadherence to treatment, increased metabolic clearance or decreased absorption of this medication. Affected subjects demonstrate resistance of the HPA axis to dexamethasone suppression, which varies depending on the severity of the condition. The dose of dexamethasone required to suppress serum cortisol concentrations by 50% may be up to 7.5-fold higher than that required to achieve the same degree of HPA axis suppression in normal subjects.
Molecular Studies
Thymidine incorporation assays and dexamethasonebinding assays on peripheral blood mononuclear cells in association with sequencing of the hGR gene are necessary to confirm the diagnosis [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . In PGGR, the thymidine incorporation assays reveal resistance to dexamethasone-induced suppression of phytohemaglutininstimulated thymidine incorporation, while the dexamethasone-binding assays often show decreased affinity of the hGR receptor for the ligand compared to control subjects [22, 27] . The opposite is true for patients with PGGH. Sequencing of the coding region of the hGR gene, including the intron/exon junctions, will reveal mutations or deletions in most but not all cases with PGGR [27, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Once a structural defect is determined, it is suggested that functional characterization of the mutant receptor should be undertaken in order to determine the molecular mechanisms through which the mutant hGR impairs glucocorticoid signal transduction.
Management
In PGGR, the aim of treatment is to suppress the excess secretion of ACTH, thereby suppressing the increased production of adrenal steroids with mineralocorticoid and androgenic activity. Treatment involves administration of high doses of mineralocorticoid-sparing synthetic glucocorticoids, such as dexamethasone (1-3 mg given once daily at night), which activate the mutant and/or wild-type hGR ␣ , and suppress the endogenous secretion of ACTH in affected subjects [20] [21] [22] . It is important to achieve adequate suppression of the HPA axis to prevent the development of an ACTH-secreting adenoma [29] . Long-term dexamethasone treatment should be carefully titrated according to the clinical manifestations and biochemical profile of the affected subjects [20] [21] [22] . In PGGH, treatment aims to address the manifestations of glucocorticoid hypersensitivity, such as dyslipidemia, diabetes type 2 and hypertension [28] .
Conclusions
The glucocorticoid receptor is a ubiquitously expressed intracellular, ligand-dependent transcription factor, which mediates the action of glucocorticoids and influences physiological functions essential for life. The stochastic nature of glucocorticoid signaling pathways in association with the variable effect that hGR gene mutations/polymorphisms might have on glucocorticoid signal transduction, indicates that alterations in hGR action may have important implications for many critical biological processes. In clinical practice, the effects of glucocorticoid treatment may vary considerably between patients and may be partly attributed to mutations or polymorphisms in the hGR gene. Therefore, when the presence of these hGR gene variants is known, the dose of glucocorticoids should be adjusted accordingly to ensure optimal therapy and minimal adverse effects.
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